Takeda Ventures, Inc. (TVI) is the corporate venture arm of Takeda Pharmaceutical Company Limited (TPC) a pharmaceutical company and the largest in Japan. TVI (formerly Takeda Research Investment, Inc.), was founded in 2001 with the vision to extend Takeda's reach into the global scientific community and to forge strategic relationships that complement and expand internal R&D capabilities. The change in name to Takeda Ventures, Inc. in 2011 reflected an intention to further leverage TVI's venture networks to engage with new scientific and business avenues for Takeda. The firm aims to encourage and support therapeutic innovation in the biopharmaceutical sector, as well as academic centers of excellence, through early stage capital investment and the provision of access to the resources of a multinational pharmaceutical company.
BiomX is a biotechnology company developing phage therapies for eradicating bacteria associated with chronic diseases.
Juventas Therapeutics is a biotechnology company founded in 2007 that is headquartered in Cleveland, Ohio developing a pipeline of regenerative therapies to treat life-threatening diseases.
Univercells is a Belgium-based bio manufacturing company founded in 2013.
OrphoMed is a clinical-stage biotechnology company with a proprietary dimer therapeutics platform. The company is focused on developing treatments for patients with gastrointestinal disorders.
Avidity Biosciences is a La Jolla-based biotechnology company.
Emendo Biotherapeutics is a New York City-based biotechnology and synthetic biology company.
A biotechnology company developing immuno-oncology therapies and therapeutic vaccines
A company focused on developing therapeutics for the treatment of depression and other central nervous system disorders
Palleon Pharmaceuticals is a Waltham, Massachusetts-based company.
A company that uses protein engineering to develop biotherapeutics
A molecular diagnostics company specializing in preterm birth, cancer and other diseases
Be Biopharma is developing a proprietary class of engineered B cells as medicines in applications beyond cytotoxicity.